Other studies have shown decreased, or even loss of, Ptch-1 expression in almost 50% of breast cancer cases—with increased Smo detected in approximately 70% of ductal carcinoma in situ (DCIS) and 30% of invasive breast carcinoma [1,4]. This evidence concerns the gene PTCH1 and ductal breast carcinoma in situ.